Back to journals
Academic Journal

MedRvix

16 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

This observational study (n=45) followed people with treatment-resistant depression receiving esketamine and found that psychedelic-like mystical experiences were common and varied widely between sessions. Higher mystical experience scores, especially positive mood and mystical feelings, were linked with greater improvement in depression symptoms, while dissociation was not.

Published
Journal
MedRvix
Authors
Mallevays, M., Fuet, L., Danon, M., Di Lodovico, L., Jaffré, C., Bouzeghoub, L., Mrad, S., Rousselet, A. V., Allary, L., Müh, C., Vissel, B., De Maricourt, P., Vinckier, F., Gaillard, R., Mekaoui, L., Gorwood, P., Petit, A. C., Berkovitch, L.
Open Accessmeta

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

This living systematic review and meta-analysis (s=6) of randomised controlled trials (n=286) found that MDMA-assisted therapy was linked to greater short-term reductions in PTSD symptoms than control treatment, with higher response and remission rates. The overall certainty of the evidence was low, and the authors noted that the online resource will be updated as new trial data emerge.

Published
Journal
MedRvix
Authors
Sevchik, B. L., Singleton, S. P., Lahey, A., Cuijpers, P., Harrer, M., Jones, M. T., Nayak, S. M., Strain, E. C., Vandekar, S. N., Yaden, D. B., Dworkin, R. H., Scott, J. C., Satterthwaite, T. D.
Open Accessindividual

Molecular, haemodynamic, and functional effects of LSD in the human brain

Using simultaneous PET–MRI in healthy volunteers, this first integrated molecular and functional neuroimaging study quantifies LSD occupancy at cerebral serotonin 2A receptors and establishes a dose–occupancy relationship while revealing an anticlockwise hysteresis between plasma levels and subjective effects. LSD produced distinct haemodynamic and functional changes — increasing global cerebral and internal carotid artery flow without altering artery diameter and reducing global connectivity (GCOR), with GCOR changes negatively correlated with CBF and differing from effects of psilocybin — findings relevant to clinical development.

Published
Journal
MedRvix
Authors
McCulloch, D. E-W., Larsen, K., Johansen, A., Johansen, S. S., Jensen, P. S., Reveles Jensen, K. H., Holze, F., Falck, N., Neufeld, V., Steenstrup, E., Andersen, T. L., Skov-Andersen, P., Spanggård, A., Geisler, M., Randrup, P. P., Shulganov, V., Nielsen, M. K. K., Svarer, C., Fisher, P. M., Knudsen, G. M., Nykjær, C. H., Stenbæk, D. S.
Open Accessindividual

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

This preprint open-label study (n=20) examines the effects of ketamine infusions (35mg/70kg, 6x) on biological ageing markers in individuals with depression (MDD) or PTSD. It finds reductions in epigenetic age as measured by OMICmAge, GrimAge V2, and PhenoAge biomarkers, as well as significant changes in Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers following a 2-3 week treatment course. The study also reports expected decreases in depression and PTSD scores as measured by PHQ-9 and PCL-5.

Published
Journal
MedRvix
Authors
Dawson, K., May, A., Carangan, J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R., Dawson, M., Mallin, M., Higgins-Chen, A. T., Dwaraka, V. B.
Open Accessindividual

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

In a sample of 863 regular meditators who had used psychedelics, 73.5% reported that psychedelic use positively influenced the quality of their meditation. Machine‑learning analyses (elastic net, random forest) identified greater frequency of psychedelic use, intentional set‑up for trips, higher agreeableness and reported N,N‑DMT exposure as the strongest predictors of perceiving such benefits, though causal claims require longitudinal or randomised studies.

Published
Journal
MedRvix
Authors
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., Schlosser, M.
Open Accessindividual

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

This retrospective analysis (n=431) of at-home ketamine treatments (1x p/w, 50-400mg lozenges) for depression, generalized anxiety, and social anxiety found statistically significant improvements in symptoms measured via PHQ-9, GAD-7, and SAD-D-10 at all follow-up time points (1-2-3 months). Minor side effects were reported by 18.8% of patients, resolving within 24 hours, and the majority concluded treatment within ≤ 6 months. No significant differences were observed between treatment-resistant and non-resistant depression outcomes.

Published
Journal
MedRvix
Authors
Swanson, Pa-C, L. N., Jones, L. S., Aycart, J. M., Zhu, Z., Rabin, D. M., Kuhn, T.

Quick Facts

Papers Indexed
16
Publisher
Medvix Publications LLC
Website
Visit